GSK•benzinga•
Regeneron, Sanofi Stock Falls After Uneven Smoker's Lung Drug Data
Summary
Regeneron and Sanofi's COPD drug itepekimab cut exacerbations by 27% in one Phase 3 trial, while the second trial did not meet its main goal.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 30, 2025 by benzinga